Analytical Data
-
基因名
CLEC2B
- Application
-
生物活性
Measured by its binding ability in a functional ELISA. When Recombinant Human AICL/CLEC-2B is coated at 2 µg/mL can bind Biotinylated Human Galectin-1 (HY-P70273). The ED50 for this effect is 3.87 µg/mL. Measured by its binding ability in a functional ELISA. When Recombinant Human AICL/CLEC-2B is coated at 2 µg/mL can bind Biotinylated Human Galectin-1 (HY-P70273). The ED50 for this effect is 3.87 µg/mL.
-
别名
C-type lectin domain family 2 member B; AICL; CLECSF2; IFNRG1
-
种属
Human
-
表达系统
HEK293
-
标签
N-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q92478
-
表达区间
K26-H149
-
蛋白长度
Extracellular Domain
-
分子量
50-65 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC2B is a C-type lectin-like receptor that plays a crucial role in the immune system by mediating various cellular responses. Understanding its structure and function is pivotal for elucidating its involvement in immune responses, particularly in the context of viral infections and inflammation. The study of CLEC2B is significant due to its potential therapeutic applications, as targeting this receptor can enhance immune responses or modulate inflammatory pathways. Recent research has focused on characterizing the recombinant forms of CLEC2B, which could provide insights into its ligand interactions and downstream signaling mechanisms. By utilizing advanced techniques in molecular biology and structural biology, scientists aim to elucidate the precise role of CLEC2B in immune regulation and its potential as a target for drug development. This research not only enhances our understanding of the innate immune system but also opens new avenues for therapeutic interventions in immune-related diseases.
